Navigation Links
Antivirals effectively curb influenza virus

Two antiviral drugs, oseltamivir and zanamivir, are highly effective when given as a preventive measure to reduce the spread of the influenza virus, according to an analysis of household-based studies by researchers at Fred Hutchinson Cancer Research Center, University of Michigan and University of Virginia, published in the current print edition of the American Journal of Epidemiology. The analysis also suggests that treatment with oseltamivir may reduce the infectiousness of influenza patients, although further studies are needed to provide a definitive conclusion.

"Preventing the spread of influenza within families is an essential part of influenza management, regardless of the strain. This study shows that there is a clear benefit to be gained by giving antivirals to people who have been exposed to the virus to prevent the onset of symptomatic illness," said lead author M. Elizabeth (Betz) Halloran, M.D., D.Sc., a Hutchinson Center-based biostatistician.

"While the efficacy of antivirals to protect against influenza is critical, the effect of these drugs on infectiousness also has important public-health consequences. Further studies to determine antiviral efficacy for reducing infectiousness would therefore be of great value," said Halloran, a member of the Hutchinson Center's Public Health Sciences Division and a professor of biostatistics at the University of Washington School of Public Health and Community Medicine.

The report evaluated four household-based, randomized, placebo-controlled clinical trials, conducted from 2000 to 2004, which were designed to estimate the effect of post-exposure antiviral treatment on preventing influenza within households. Two of the trials were conducted with zanamivir and two with oseltamivir, permitting comparisons to be made between the two. The trials covered a total of 1,475 households. The majority of first household cases (53 percent to 70 percent) had influenza A (H3N2 or H1N1).

The authors reviewed the effects of each antiviral on infectiousness and pathogenicity ?the ability of the influenza virus to cause overt disease. Pathogenicity in controls ranged from 44 percent to 66 percent. Efficacy in reducing pathogenicity for zanamivir was 52 percent and 56 percent in the two zanamivir studies; for oseltamivir, it was 56 percent and 79 percent. The researchers found that both drugs were highly preventive against influenza illness, with oseltamivir at 81 percent efficacy and zanamivir at 75 percent. Thus, the preventive use of either product reduced by 75 percent to 81 percent the chance that an exposed person would become ill with influenza.

The researchers' analysis found a significant reduction in infectiousness, as defined by reductions in influenza illnesses in household contacts, when oseltamivir was used for treatment of ill persons, but not when zanamivir was administered. Although these results are of interest, the authors stress that the numbers were small and combined estimates from two studies for each drug were used in both instances. Furthermore, oseltamivir treatment of ill persons did not appear to reduce the frequency of influenza infection in their contacts.

In exploring the reasons for oseltamivir's greater effects on infectiousness, the authors speculated that the different modes of administration ?oral for oseltamivir and inhaled for zanamivir ?and resultant upper-respiratory viral levels could be the key, with zanamivir not reaching or affecting influenza virus in the nose. While both antivirals reduced cough, in earlier studies inhaled zanamivir did not significantly reduce nasal symptoms. In the paper the authors discussed the possibility that infectious droplets inhaled and exhaled from the nose may be important in viral transmission, thus orally administered oseltamivir might have an advantage in limiting spread.

In addressing the limitations to their research, the authors call for further stu dies into antiviral efficacy.

"Trials in non-household settings where influenza readily spreads ?such as schools, homes for the elderly and workplaces ?would be beneficial not only for planning management of seasonal influenza but also would be invaluable in pandemic planning. Additionally, simple solutions such as standardized randomization and study criteria would greatly facilitate trial comparison in the future. Such further studies will help us ensure we are better prepared not only for annual influenza seasons but also for the ultimate pandemic," said co-author Ira M. Longini, Jr., Ph.D., also a member of the Hutchinson Center's Public Health Sciences Division and a biostatistics professor at the University of Washington.


'"/>

Source:Fred Hutchinson Cancer Research Center


Related biology news :

1. New study: Sexually transmitted disease treatment can be effectively administered by sex partners
2. New vaccine protects more effectively against tuberculosis
3. Bird flu study highlights need to vaccinate flocks effectively
4. Experimental RNA-based drug kills prostate cancer cells effectively and safely
5. Computers to be used to find blueprint for new influenza drug
6. Less virulent strains of avian influenza can infect humans
7. Drug resistant avian influenza viruses more common in Southeast Asia than North America
8. New vaccine platform may fight infections with causes from influenza to bioterrorism
9. First big influenza genome study reveals flu evolution
10. Web model of influenza-host lifecycles will aid scientists in creating anti-viral drugs
11. New influenza vaccine takes weeks to mass produce
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/28/2016)... -- "The biometric system market projected ... biometric system market is in the growth stage and ... The biometric system market is expected to be valued ... of 16.79% between 2016 and 2022. Government initiative in ... smartphones, rising use of biometric technology in financial institutes ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... ... for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion medium. ... media products engineered to radically streamline culture processes, minimize processing time, significantly ...
(Date:12/8/2016)... 2016  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a ... plans to commercialize innovative therapeutics for patients with ... were approved for trading on the OTCQX U.S. ... OTCQX, effective today, under the ticker symbol "HPPI." ... companies must meet high financial standards, follow best ...
(Date:12/7/2016)... ... 07, 2016 , ... ACEA Biosciences, Inc. presented today updated ... trial for its lead drug candidate, AC0010, at the World Conference on Lung ... determine the safety, antitumor activity, and recommended phase II dosage of AC0010 in ...
(Date:12/7/2016)... 7, 2016 /PRNewswire/ - Zenith Capital Corp. ("Zenith" or the "Company") ... presented at the Company,s Annual and Special Meeting. ... take place on Thursday, December 15, 2016 at ... (Room EC1040), 4825 Mount Royal Gate SW, Calgary, ... of meeting and management information circular, containing the matters to ...
Breaking Biology Technology: